Our aim is to emphasize the importance of early diagnosis and close multidisciplinary monitoring of these patients.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Transient myeloproliferative disease (TMD) is among the main hematologic problems seen in neonates with Down syndrome (DS).
📊
Key Findings & Data:It is usually self-limiting and results in spontaneous remission within 3 to 6 months.
💡
Conclusion & Impact:Our aim is to emphasize the importance of early diagnosis and close multidisciplinary monitoring of these patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Transient myeloproliferative disease (TMD) is among the main hematologic problems seen in neonates with Down syndrome (DS). It is usually self-limiting and results in spontaneous remission within 3 to 6 months. Characteristic signs of TMD are leukocytosis, thrombocytopenia, anemia, hepatosplenomegaly, cutaneous nodules, and increased numbers of circulating blasts. In this article, we present a DS neonate without leukocytosis who was diagnosed as having TMD after a diffuse vesiculopapular eruption on the face, which is a different clinical presentation than other cases in the literature. Our aim is to emphasize the importance of early diagnosis and close multidisciplinary monitoring of these patients.
🔖
Cite This Article
Cakir, U., Tayman, C., Gokcebay, D. G., Ceran, B., Derme, T., Erkan, M. O., Sahin, S. (2022). A down syndrome patient diagnosed with transient myeloproliferative disease after presenting with cutaneous findings. Annals of Medical Research, Cilt: 28 - Sayı: 10, 1945–1948. https://ajindex.com/articles/445765
Zipursky A. Transient leukaemia--a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 2003;120:930-8
Pine SR, Guo Q, Yin C, et al. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood 2007;110:2128-31
Roberts I, Alford K, Hall G, Juban G, Richmond H. GATA1- mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood 2013;122:3908- 17
Gamis AS, Alonzo TA, Gerbing RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood 2011;118:6752-96
Boos M, Wine Lee L, Freedman JL, et al. Presentation of acute megakaryoblastic leukemia associated with a GATA1 mutation mimicking the eruption of transient myeloproliferative disorder. Pediatr Dermatol. 2015;32:204-7
Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood 2006;107:4606-13
Klusmann JH, Creutzig U, Zimmerman M, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 2008;111:2991-8
Hayashi Y, Eguchi M, Sugita K, et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down’s syndrome. Blood 1988;72:15-23
Tugcu AU, Apak BB, Ince-Anuk D, et al. Transient Abnormal Myelopoiesis in a Newborn with Mosaic Down Sydrome. Turk J Pediatr 2019;13:496-8
Narvaez-Rosales V, de-Ocariz MS, Carrasco-Daza D, et al. Neonatal vesiculopustular eruption associated with transient myeloproliferative disorder: report of four cases. Int J Dermatol 2013;52:1202-9
Nijhawan A, Baselga E, Gonzalez-Ensenat MA, et al. Vesiculopustular eruptions in Down syndrome neonates with myeloproliferative disorders. AMA Arch Derm 2001;137:760-3
Alford KA, Reinhardt K, Garnett C, et al. International Myeloid Leukemia-Down Syndrome Study Group. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood 2011;118:2222-8
Roy A, Roberts I, Vyas P. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome. Semin Fetal Neonatal Med 2012;17:196-201.